BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 14993336)

  • 1. Selective inhibitors of cyclooxygenase-2: a growing class of anti-inflammatory drugs.
    Mardini IA; FitzGerald GA
    Mol Interv; 2001 Apr; 1(1):30-8. PubMed ID: 14993336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The new COX-2 inhibitors: rofecoxib (Vioxx) and celecoxib (Celebrex).
    Wynn RL
    Gen Dent; 2000; 48(1):16-20. PubMed ID: 11199547
    [No Abstract]   [Full Text] [Related]  

  • 3. The coxibs, selective inhibitors of cyclooxygenase-2.
    FitzGerald GA; Patrono C
    N Engl J Med; 2001 Aug; 345(6):433-42. PubMed ID: 11496855
    [No Abstract]   [Full Text] [Related]  

  • 4. [Specific inhibitors of cyclooxygenase-2 (COX-2): current knowledge and perspectives].
    Rioda WT; Nervetti A
    Acta Biomed Ateneo Parmense; 2001; 72(3-4):55-64. PubMed ID: 11889908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of cyclooxygenase-2-specific inhibitors.
    Cannon GW; Breedveld FC
    Am J Med; 2001 Feb; 110 Suppl 3A():6S-12S. PubMed ID: 11173044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COX-2-specific inhibition: implications for clinical practice.
    Pascucci RA
    J Am Osteopath Assoc; 1999 Nov; 99(11 Suppl):S18-22. PubMed ID: 10643177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence.
    Rahme E; Barkun AN; Toubouti Y; Bardou M
    Gastroenterology; 2003 Aug; 125(2):404-12. PubMed ID: 12891542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapeutic advances with coxibs: few certainties and a lot of doubts].
    Jouzeau JY; Daouphars M; Netter P
    Therapie; 2004; 59(2):207-11. PubMed ID: 15359614
    [No Abstract]   [Full Text] [Related]  

  • 9. COX-2 inhibitors: better than traditional NSAIDs? Vioxx and Celebrex may be no less risky than NSAIDs.
    Atkinson HG
    Health News; 2002 Aug; 8(8):5. PubMed ID: 12206146
    [No Abstract]   [Full Text] [Related]  

  • 10. The prevalence of cardiorenal risk factors in patients prescribed nonsteroidal anti-inflammatory drugs: data from managed care.
    Harley C; Wagner S
    Clin Ther; 2003 Jan; 25(1):139-49. PubMed ID: 12637116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The new NSAIDs: cox-2 inhibitors.
    Capriotti T
    Medsurg Nurs; 2000 Dec; 9(6):313-7. PubMed ID: 11904867
    [No Abstract]   [Full Text] [Related]  

  • 12. Celecoxib and rofecoxib. The role of COX-2 inhibitors in dental practice.
    Moore PA; Hersh EV
    J Am Dent Assoc; 2001 Apr; 132(4):451-6. PubMed ID: 11315375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database.
    Zhao SZ; Reynolds MW; Lejkowith J; Whelton A; Arellano FM
    Clin Ther; 2001 Sep; 23(9):1478-91. PubMed ID: 11589261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A clinical audit of the prescribing of celecoxib and rofecoxib in Australian rural general practice.
    Cutts C; LaCaze A; Tett S
    Br J Clin Pharmacol; 2002 Nov; 54(5):522-7. PubMed ID: 12445032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An update on specific COX-2 inhibitors: the COXIBs.
    Gupta S; Crofford LJ
    Bull Rheum Dis; 2001; 50(1):1-4. PubMed ID: 12092091
    [No Abstract]   [Full Text] [Related]  

  • 16. Cox-2 inhibitors: today and tomorrow.
    McMurray RW; Hardy KJ
    Am J Med Sci; 2002 Apr; 323(4):181-9. PubMed ID: 12003372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial.
    Geba GP; Weaver AL; Polis AB; Dixon ME; Schnitzer TJ;
    JAMA; 2002 Jan; 287(1):64-71. PubMed ID: 11754710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Specific inhibitors of cyclooxygenase type 2] ].
    Tomasová-Studýnková J
    Vnitr Lek; 2002 May; 48(5):403-8. PubMed ID: 12061207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Coxibs, which real therapeutic advance?: Recent pharmacoepidemiological data].
    Montastruc JL; Lapeyre-Mestre M; Gony M; Lugardon S; Bagheri H
    Therapie; 2004; 59(2):201-5. PubMed ID: 15366126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.
    Hochberg MC
    Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S15-22. PubMed ID: 11695246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.